 NEW YORK, June 18, 2021 GLOBE NEWSWIRE -- TG Therapeutics, Inc. NASDAQ: TGTX, today announced the presentation of data from the ULTIMATE I II global, active controlled, Phase 3 trials evaluating ublituximab, the Companys investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide, in patients with relapsing forms of multiple sclerosis RMS, during the 7th Congress of the European Academy of Neurology EAN. This data was previously presented at the American Academy of Neurology AAN 73rd Annual Meeting. 